Ep. 182 - Drug Pricing, Generics, and IP Reform w/John Murphy

Prescription drug prices dominate the headlines — but most Americans rely on medicines that rarely get discussed. On this episode of the Federal Newswire Lunch Hour Podcast, host Andrew Langer sits down with John Murphy, President and CEO of the Association for Accessible Medicines, to unpack the critical — and often overlooked — role that generic drugs and biosimilars play in the U.S. healthcare system. Murphy explains why generics make up nearly 90% of prescriptions in the United States while accounting for only a fraction of total drug spending — and why that imbalance reveals deeper structural issues in how medicines are priced, patented, and brought to market. A major focus of the conversation is the growing tension between pharmaceutical innovation and affordability. Murphy breaks down how the current system of patents and exclusivity — originally designed to balance innovation with competition — has evolved in ways that can delay generic entry and extend high prices far beyond what was originally intended. The discussion also explores: • The difference between statutory exclusivity and patent protection • How “follow-on” patents and minor modifications can extend drug monopolies • Why generic competition is less effective today than in the past • The role of pharmacy benefit managers (PBMs) and rebate structures • How pricing incentives can sometimes favor higher-cost brand drugs over generics • The growing importance of biosimilars — and why the U.S. lags behind Europe • The legal and regulatory barriers slowing biosimilar adoption • Why patent litigation is significantly more complex in the U.S. than abroad • The impact of global conflicts on supply chains, input costs, and drug availability • How shipping, energy costs, and geopolitics affect the generic drug market Murphy also highlights the national security implications of the generic drug industry, arguing that access to affordable antibiotics, anti-infectives, and essential medicines is just as critical as breakthrough innovation. The conversation ultimately raises a central question: how can the United States preserve medical innovation while ensuring that patients have timely access to affordable treatments? 00:00 — Introduction and John Murphy joins the podcast 00:48 — Why generics are the backbone of U.S. medicine 02:29 — Generics vs brand drugs: volume vs spending 04:11 — Innovation, IP protection, and the “virtuous cycle” 05:22 — Statutory exclusivity vs patent protection explained 07:19 — “Evergreening” and follow-on patents 09:24 — Inhalers, delivery systems, and patent extensions 11:10 — Controlled release drugs and market behavior 13:50 — PBMs, rebates, and pricing distortions 16:10 — Real-world example: generics vs high-priced alternatives 17:20 — Why IP reform is central to lowering costs 20:01 — Legal battles over generic entry and Supreme Court case 22:14 — Biosimilars vs generics: what’s the difference? 24:03 — Why Europe leads in biosimilars adoption 26:11 — Patent barriers and manufacturing challenges in the U.S. 28:38 — Quality concerns and global manufacturing realities 31:25 — Supply chain pressures and rising costs 33:00 — National security and the importance of generics 35:55 — Final thoughts and where to learn more